Risk score model for the development of hepatocellular carcinoma in treatment-naive patients receiving oral antiviral treatment for chronic hepatitis B
- Authors
- Sohn, Won; Cho, Ju-Yeon; Kim, Ji Hoon; Lee, Jung Il; Kim, Hyung Joon; Woo, Min-Ah; Jung, Sin-Ho; Paik, Yong-Han
- Issue Date
- Jun-2017
- Publisher
- KOREAN ASSOC STUDY LIVER
- Keywords
- Chronic hepatitis B; Hepatocellular carcinoma; Assessment, Risk; Antiviral drugs
- Citation
- CLINICAL AND MOLECULAR HEPATOLOGY, v.23, no.2, pp 170 - 178
- Pages
- 9
- Journal Title
- CLINICAL AND MOLECULAR HEPATOLOGY
- Volume
- 23
- Number
- 2
- Start Page
- 170
- End Page
- 178
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/4413
- DOI
- 10.3350/cmh.2016.0086
- ISSN
- 2287-2728
2287-285X
- Abstract
- Background/Aims: This study aimed to develop and validate a risk prediction model for the development of hepatocellular carcinoma (HCC) in treatment-naive patients receiving oral antiviral treatment for chronic hepatitis B (CHB). Methods: We investigated 2,061 Korean treatment-naive patients with CHB treated with entecavir as an initial therapy. A risk score model for HCC development was developed based on multivariable Cox regression model in a single center (n=990) and was validated using the time-dependent area under the receiver operating characteristic curve (AUROC) in three other centers (n=1,071). The difference of HCC development among risk groups (low, intermediate, and high) categorized by risk score was also investigated. Results: The cumulative incidence rates of HCC at 5 years were 11.2% and 8.9% in the testing and validation cohorts, respectively. HCC-Risk Estimating Score in CHB patients Under Entecavir (HCC-RESCUE) is formulated as (age+15xgender [female=0/male=1]+23xcirrhosis [absence=0/presence=1]). The AUROCs at 1 year, 3 years, and 5 years were 0.82, 0.81, and 0.81, respectively, in the validation cohort. A significant difference of HCC development in each risk group was determined by the 5-year HCC risk score in the validation cohort (low risk group, 2.1%; intermediate risk group, 9.3%; high risk group, 41.2%, p<0.001). Conclusions: The study presents a new risk score model with a good ability to predict HCC development and determine high risk patients for HCC development consisting of readily available clinical factors in treatment-naive CHB patients receiving entecavir.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/4413)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.